KwaZulu-Natal center for HIV and tuberculosis clinical trials
Official title: KwaZulu-Natal Clinical Trials Unit
Funded at Centre/aids Programme/res/south Africa · NIH-11397677 · Data updated 2026-11-12
Runs clinical trials testing new HIV prevention and treatment approaches for people in KwaZulu-Natal, including adolescents and adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Centre/aids Programme/res/south Africa NIH-funded |
| Lab location | 1 site (Durban, SOUTH AFRICA) |
| Project start | December 1, 2024 |
| Project end | November 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $442,022 |
| NIH project number | 3UM1AI069469-20S1 |
| Project ID | NIH-11397677 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living in or near KwaZulu-Natal who are adolescents or adults at risk for HIV or with HIV/TB and willing to join clinical research visits and follow-up would be the best match.
✕Less likely to help
People who live far from the Durban sites, who do not meet a specific trial's eligibility rules, or who need immediate guaranteed treatment may not directly benefit from participation.
What this research studies
You would take part at clinics run by experienced teams from CAPRISA and the South African Medical Research Council in Durban, which run many HIV and TB trials. The unit combines eight clinical research sites with shared leadership, coordination, and support cores to manage studies and keep high follow-up rates. They test prevention tools (for example the CAPRISA 256 antibody), PrEP strategies, and treatment approaches for people at risk of or living with HIV and tuberculosis. The teams aim to enroll and retain participants from priority populations so new tools can reach the communities hardest hit by HIV/TB.
Why it matters
Potential benefit: Could speed access to new HIV prevention tools and better treatment strategies for people at high risk or living with HIV/TB in the region.
How similar studies have gone: Teams from these sites have contributed to proven advances such as tenofovir-based PrEP, improved HIV–TB co-treatment strategies, and reduced breastfeeding transmission with nevirapine, so the approach builds on prior successful work.
Where this research is happening
-
Centre/aids Programme/res/south Africa
Durban, South Africa Active
Researchers
- Principal investigator: Abdool Karim, Quarraisha — Centre/aids Programme/res/south Africa
- Study coordinator: Abdool Karim, Quarraisha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.